Natalizumab Subcutaneous Immunogenicity and Safety Study

NCT02142192 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision.

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: natalizumab

Sponsor

Biogen